Suppr超能文献

奥曲肽治疗长期恶性肠梗阻二例报告。

Octreotide for long-lasting malignant bowel obstruction: two case reports.

机构信息

Main Regional Center for Pain Relief and Supportive/Palliative Care, La Maddalena Cancer Center, Palermo, Italy; Regional Home Palliative Care Program SAMOT, Palermo, Italy.

Regional Home Palliative Care Program SAMOT, Palermo, Italy.

出版信息

Ann Palliat Med. 2024 Jan;13(1):183-186. doi: 10.21037/apm-23-311.

Abstract

BACKGROUND

Efficacy of the combination of octreotide and other drugs for the management of malignant bowel obstruction (MBO) has been well described. However, long-lasting stages with lack of stool emission are a challenging clinical condition of MBO that have never described.

CASE DESCRIPTION

We describe two cases in which the addition of octreotide to supportive care measures, even given late after more than 3 weeks of no stool emission, resulted to be still effective in recovering the bowel transit. In the first case, a patient admitted to home palliative care had a nasogastric tube and reported to not have stool emission and passing gas for 25 days. Two days after starting the combination of octreotide and other drugs, the patient evacuated and the nasogastric tube was removed, without reporting nausea or episodes of vomiting. In the second case, a patient admitted to an acute palliative care unit, the patient had no stool emission for more than 3 weeks. A nasogastric tube was placed and comprehensive palliative care treatment was provided. Two days after starting a combination of octreotide and other drugs, the nasogastric tube was removed, without reporting vomiting. In both cases, bowel transit recovered and patients were able to initiate oral nutrition.

CONCLUSIONS

The combination of octreotide with other drugs described for standard treatment for the management of MBO, should be attempted even in patients with very long periods of lack of feces emission.

摘要

背景

奥曲肽与其他药物联合治疗恶性肠梗阻(MBO)的疗效已有充分描述。然而,MBO 缺乏粪便排放的长期阶段是一种具有挑战性的临床情况,尚未有相关描述。

病例描述

我们描述了两例病例,在没有粪便排放超过 3 周后,即使在晚期,奥曲肽联合支持治疗措施仍能有效恢复肠道转运。在第一个病例中,一名接受家庭姑息治疗的患者有一个鼻胃管,报告说已经 25 天没有排便和放屁。在开始使用奥曲肽和其他药物联合治疗的两天后,患者开始排便,并且拔除了鼻胃管,没有出现恶心或呕吐发作。在第二个病例中,一名患者入住急性姑息治疗病房,已经超过 3 周没有排便。放置了鼻胃管,并提供了全面的姑息治疗。在开始使用奥曲肽和其他药物联合治疗的两天后,鼻胃管被移除,没有出现呕吐。在这两个病例中,肠道转运都恢复了,患者能够开始口服营养。

结论

即使在有很长时间缺乏粪便排放的患者中,奥曲肽与其他药物联合治疗也应尝试用于 MBO 标准治疗。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验